OCUL Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
12.9M
-4.5%
13.5M
+24.9%
10.8M
-18.6%
13.3M
-8.9%
14.5M
Cost of Revenue
1.5M
-27.6%
2.0M
+51.3%
1.3M
-16.6%
1.6M
-10.1%
1.8M
Gross Profit
11.4M
-0.4%
11.5M
+21.2%
9.5M
-18.9%
11.7M
-8.7%
12.8M
Operating Expenses
109.3M
+16.8%
93.6M
-9.0%
102.8M
+26.3%
81.4M
-0.1%
81.5M
R&D
74.8M
+38.1%
54.1M
-18.2%
66.2M
+30.3%
50.8M
-3.0%
52.4M
SG&A
34.5M
-12.5%
39.4M
+7.8%
36.6M
+19.5%
30.6M
+5.2%
29.1M
Operating Income
-97858000
-19.2%
-82109000
+12.0%
-93340000
-33.8%
-69760000
-1.5%
-68698000
EBITDA
-95427000
-18.9%
-80258000
+12.8%
-92057000
-34.4%
-68513000
-1.3%
-67629000
Net Income
-94782000
-20.3%
-78763000
+11.1%
-88612000
-37.1%
-64654000
+6.9%
-69418000
EPS (Basic)
$-0.42
-20.0%
$-0.35
+12.5%
$-0.40
-37.9%
$-0.29
+23.7%
$-0.38
EPS (Diluted)
$-0.42
-20.0%
$-0.35
+12.5%
$-0.40
-37.9%
$-0.29
+23.7%
$-0.38
Shares (Diluted)
225.5M
+0.3%
225.0M
+0.4%
224.1M
+0.5%
223.1M
+21.3%
183.9M
Ocular Therapeutix (OCUL) — Financials